The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of ...

"In this high-risk population with relapsed and refractory disease and extensive prior therapy, pirtobrutinib demonstrated ...

SAN DIEGO -- Treatment with an investigational oral inhibitor of Bruton's tyrosine kinase (BTK) was safe and boosted platelet ...

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...

Data from the Phase I/II TRANSCEND CLL 004 study evaluating the combination of Bristol Myers Squibb’s (BMS’s) Breyanzi ...

A fixed duration combination of venetoclax with acalabrutinib, with or without obinutuzumab, was superior to standard ...

BTIG initiated coverage of Nurix Therapeutics (NRIX) with a Buy rating and $35 price target Nurix is a protein degrader company whose lead ...

Sanofi reports positive Phase III results for its BTK inhibitor in treating immune thrombocytopenia, demonstrating faster ...

Sanofi-Aventis Groupe announced positive results from the pivotal LUNA 3 phase 3 study of rilzabrutinib in adults with persistent or ...

Tolebrutinib is a small molecule commercialized by Sanofi, with a leading Phase III program in Secondary Progressive Multiple Sclerosis (SPMS).

New Delhi: Pharmaceutical major Glenmark Pharmaceuticals has got the go-ahead from the Subject Expert Committee (SEC) ...